Search clinical trials for: MVA-BN-WEV Dose 1

Total 1116 results

Bavarian Nordic
JPM CBRN Medical

Completed

Vaccination Trial of a Recombinant MVA-BN-WEV Vaccine in Healthy Adult Subjects

Equine Encephalitis

United States
Bavarian Nordic

Completed

Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy Subjects

Smallpox

Germany
Bavarian Nordic

Completed

Trial to Evaluate the Safety, Tolerability and Immunogenicity of the Recombinant MVA BN® RSV Vaccine

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Phase II Study on Immunogenicity and Safety of MVA-BN® (IMVAMUNE™) Smallpox Vaccine in Subjects With Atopic Dermatitis

Atopic Dermatitis

United States, Mexico
Bavarian Nordic

Completed

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer

Solid Metastatic Tumor

United States
Bavarian Nordic

Completed

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Metastatic Breast Cancer

Breast Cancer

United States
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in HIV Infected Patients

HIV Infections

United States
Bavarian Nordic
Biomedical Advanced Research and Development Authority

Completed

Freeze-Dried MVA-BN® Lot Consistency Smallpox Trial

Smallpox

United States
Bavarian Nordic

Withdrawn

RSV-MVA-BN Vaccine Phase I Trial, Intranasal Application in Adults.

Respiratory Syncytial Virus Infections
MRC/UVRI and LSHTM Uganda Research Unit
Epicentre, Paris, France.; Janssen Pharmaceutica N.V., Belgium; Coalition for... and other collaborators

Completed

ZEBOVAC (Ebola Vaccine Trial, Ad26.ZEBOV/MVA-BN-Filo)

Ebola Virus Disease

Uganda
Bavarian Nordic

Completed

RSV-MVA-BN Vaccine Phase II Trial in ≥ 55 Year Old Adults

Respiratory Syncytial Virus Infections

United States
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Randomized, Double-blind, Placebo-controlled Study on Immunogenicity and Safety of MVA-BN (IMVAMUNE™) Smallpox Vaccine in Healthy Subjects

Smallpox

Germany
University of Oxford
National Institute of Allergy and Infectious Diseases (NIAID); Wellcome Trust

Completed

A Study to Assess New Ebola Vaccines, cAd3-EBO Z and MVA-BN® Filo

Ebola | Ebola Zaire

United Kingdom
Bavarian Nordic

Completed

A Safety and Immunology Study of a Modified Vaccinia Vaccine for HER-2(+) Breast Cancer After Adjuvant Therapy

Breast Cancer

United States
Bavarian Nordic

Completed

A Safety Trial of MVA-BN®-PRO in Men With Androgen-Insensitive Prostate Cancer (BNIT-PR-001)

Androgen-insensitive Prostate Cancer

United States
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Dose-finding Study to Evaluate Immunogenicity of Three Different Dose Levels of the IMVAMUNE (MVA-BN) Smallpox Vaccine.

Smallpox

Switzerland
Bavarian Nordic
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

Safety, Tolerability and Immune Response of IMVAMUNE (MVA-BN)Smallpox Vaccine in Patients With Atopic Disorders

Dermatitis, Atopic | Hay Fever

Germany
Bavarian Nordic
US Army Medical Research Institute of Infectious Diseases

Completed

A Non-inferiority Trial to Compare MVA-BN® Smallpox Vaccine to ACAM2000®

18-42 Year Old Healthy Vaccinia-naïve Subjects

Korea, Republic of
Bavarian Nordic
National Institutes of Health (NIH)

Completed

Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients

HIV Infections

United States, Puerto Rico
University of Utah
Genentech, Inc.; Bavarian Nordic

Withdrawn

Perioperative Atezolizumab With MVA-BN-Brachyury and PROSTVAC For Intermediate-Risk And High-Risk Localized Prostate Cancer (AtezoVax)

Prostate Adenocarcinoma

United States
Janssen Vaccines & Prevention B.V.
National Institute of Allergy and Infectious Diseases (NIAID)

Completed

A Study to Evaluate Safety, Tolerability, and Immunogenicity of Heterologous Prime-boost Regimens Using the Multivalent Filovirus Vaccines Ad26.Filo and MVA-BN-Filo Administered in Different Sequences and Schedules in Healthy Adults

Healthy

United States
Bavarian Nordic

Completed

Safety and Tolerability Trial (MVA-BN-Brachyury/FPV-Brachyury)

Safety Issues

United States
National Institute of Allergy and Infectious Diseases...

Completed

Safety, Reactogenicity and Immunogenicity of MVA in Hematopoietic Stem Cell Transplant (HSCT) Subjects

Variola Major (Smallpox)

United States
University of Oxford
European Commission

Completed

A Phase Ia Clinical Trial to Assess the Safety and Immunogenicity of New Plasmodium Falciparum Malaria Vaccine Candidates ChAd63 RH5 Alone and With MVA RH5

Malaria | Plasmodium Falciparum

United Kingdom
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; Centre Muraz and other collaborators

Completed

Safety, Tolerability and Immunogenicity Study of 3 Prime-boost Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo in Healthy Adults, Children and Human Immunodeficiency Virus Positive (HIV+) Adults

Hemorrhagic Fever, Ebola

Kenya, Uganda, Burkina Faso, Côte D'Ivoire
Janssen Vaccines & Prevention B.V.
Walter Reed Army Institute of Research (WRAIR)

Completed

Safety, Tolerability and Immunogenicity Study of 2-dose Heterologous Regimens for Ebola Vaccines Ad26.ZEBOV/MVA-BN-Filo

Hemorrhagic Fever, Ebola

United States, Uganda, Kenya, Mozambique, Nigeria, Tanzania
Crucell Holland BV

Completed

A Safety and Immunogenicity Study of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United Kingdom
Institute of Medical Biology, Chinese Academy of...
Guangxi Center for Disease Control and Prevention

Completed

Clinic Trial to Evaluate the Safety and Immunogenicity by Different Sequential Schedules of bOPV and IPV

Poliomyelitis

China
Universitätsklinikum Hamburg-Eppendorf
Erasmus Medical Center; German Center for Infection Research; Coalition for Epidemic... and other collaborators

Active, not recruiting

Safety and Immunogenicity of the Candidate Vaccine MVA-MERS-S_DF-1 Against MERS (MVA-MERS-S)

MERS (Middle East Respiratory Syndrome)

Germany, Netherlands
London School of Hygiene and Tropical Medicine
Public Health England; Janssen Vaccines & Prevention B.V.; Epicentre; Coalition... and other collaborators

Active, not recruiting

Effectiveness and Safety of a Heterologous, Two-dose Ebola Vaccine in the DRC

Ebola Virus Disease

Congo, The Democratic Republic of the
Janssen Vaccines & Prevention B.V.
Institut National de la Santé Et de la Recherche Médicale, France; University...

Completed

A Study to Assess Safety, Tolerability, and Immunogenicity of Three Heterologus 2-dose Regimens of the Candidate Prophylactic Vaccines for Ebola in Healthy Adults

Ebola Viral Disease

France, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

Safety of and Immune Response to Two HIV Vaccine Formulations (rMVA-HIV and rFPV-HIV) Alone or in Combination in HIV Uninfected Adults

HIV Infections

United States, Brazil
Bavarian Nordic

Completed

A Trial to Evaluate Immunogenicity and Safety of Three Consecutive Production Lots of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in Healthy, Vaccinia-naïve Subjects

Smallpox

United States
National Institute of Allergy and Infectious Diseases...

Completed

A Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA-720 Adjuvant in 18-45 Year Old Healthy Volunteers

Yellow Fever | Yellow Fever Immunisation

United States
Nouscom SRL

Active, not recruiting

Nous-PEV: a Novel Immunotherapy for Lung Cancer and Melanoma

Melanoma (Skin) | Non-Small-Cell Lung Carcinoma

Belgium, Spain, United Kingdom
Alexion Pharmaceuticals, Inc.

Recruiting

Study of Ravulizumab in Immunoglobulin A Nephropathy (IgAN) (ICAN)

Immunoglobulin A Nephropathy | IgAN

Spain, United Kingdom, United States, Italy, Korea, Republic of, Belgium, Germany, Colombia, Japan, China, France, Saudi Arabia, Thailand, Australia, Canada, Brazil, Malaysia, Poland, Taiwan, Austria, Greece, Israel, Netherlands, Arge... and more
Janssen Vaccines & Prevention B.V.
Emory University; Coalition for Epidemic Preparedness Innovations; Center for...

Completed

A Study of a 2-dose Ebola Vaccine Regimen of Ad26.ZEBOV Followed by MVA-BN-Filo in Healthy Pregnant Women (INGABO)

Healthy

Rwanda
Janssen Vaccines & Prevention B.V.

Completed

A Safety and Immunogenicity Study of Heterologous and Homologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

United States
Crucell Holland BV

Completed

A Study to Evaluate the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Kenya
Crucell Holland BV

Completed

A Study to Assess the Safety and Immunogenicity of Heterologous Prime-Boost Ebola Vaccine Regimens in Healthy Participants

Healthy

Tanzania, Uganda
Janssen Vaccines & Prevention B.V.

Completed

A Study to Evaluate A Range of Dose Levels of Ad26.ZEBOV and MVA-BN-Filo in Healthy Adult Participants

Healthy

United States
Bavarian Nordic

Completed

Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection

Smallpox

United States, Puerto Rico
National Cancer Institute (NCI)

Active, not recruiting

Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT)

Metastatic Cancer | Solid Tumors

United States
Aronora, Inc.

Completed

Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects

Thrombosis

United States
Cortria Corporation

Completed

A Study to Evaluate the Lipid Regulating Effects of TRIA-662

Hyperlipidemia
Aronora, Inc.
Celerion

Completed

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

Thrombosis | End Stage Renal Disease

United States
Janssen Vaccines & Prevention B.V.
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Completed

Staged Phase 3 Study to Assess the Safety and Immunogenicity of Ebola Candidate Vaccines Ad26.ZEBOV and MVA-BN-Filo (EBOVAC-Salone)

Ebola Virus Disease

Sierra Leone
Centers for Disease Control and Prevention
Bavarian Nordic; Kinshasa School of Public Health; Ministry of Public Health,...

Active, not recruiting

JYNNEOS Smallpox Vaccine in Adult Healthcare Personnel at Risk for Mpox in the Democratic Republic of the Congo

Monkeypox Virus Infection

Congo, The Democratic Republic of the
University of Maryland, Baltimore
National Institute of Allergy and Infectious Diseases (NIAID); Wellcome Trust; Leidos Biomedical Research, Inc...

Completed

Phase 1 Trial of Ebola Vaccine in Mali

Ebola Virus Disease | Hemorrhagic Fever

Mali
National Institute of Allergy and Infectious Diseases...
London School of Hygiene and Tropical Medicine; Institut National de la Santé... and other collaborators

Active, not recruiting

Partnership for Research on Ebola VACcinations (PREVAC)

Ebola Virus Disease

Guinea, Liberia, Mali, Sierra Leone

Search clinical trials for: MVA-BN-WEV Dose 1

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Kingdom

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations